Accesso libero

Evaluation of methylation profiles of an epidermal growth factor receptor gene in a head and neck squamous cell carcinoma patient group

INFORMAZIONI SU QUESTO ARTICOLO

Cita

Figure 1

Amplification curves of methylated reactions from both HNSCC and healthy control groups.* Positive methylation control.
Amplification curves of methylated reactions from both HNSCC and healthy control groups.* Positive methylation control.

Figure 2

Amplification curves of unmethylated reactions from both HNSCC and healthy control groups.* Positive methylation control.
Amplification curves of unmethylated reactions from both HNSCC and healthy control groups.* Positive methylation control.

Polymerase chain reaction primers for methylated and unmethylated DNA sequences for the EGFR gene.

Primer NameSequences (5’>3’)PCR Product
EGFR-M ForwardTGT TTT TTT CGC GTT TCG GTT CGC GC150 bp
EGFR-M ReverseCGT CTA AAC GAC GAC GAC CGC CG
EGFR-UM ForwardTGT TTT GTT TTT TTG TGT TTT GGT TTG TGT
EGFR-UM ReverseCAT CCA ATC TAA ACA ACA ACA ACC ACC A150 bp

Determination of methylation profile after methylation-specific-polymerase chain reaction.

MS-PCR
MethylatedUnmethylatedMethylation Profile
[–][+]unmethylated
[+][–]methylated
[+][+]methylated
[–][–]excluded from study

Methylation profiles of control and patient groups.

Control GroupMS-PCRMethylation ProfilePatient GroupMS-PCRMethylation Profile
CtMCtUMCtMCtUM
Positive Controla27.33[+]40.00[–]MPositive Controla27.33[+]40.00[–]M
C-134.37[+]32.28[+]MP-133.72[+]31.41[+]M
C-232.86[+]30.67[+]MP-229.87[+]29.77[+]M
C-331.43[+]28.88[+]MP-333.21[+]31.95[+]M
C-432.92[+]29.35[+]MP-431.68[+]29.50[+]M
C-531.82[+]29.74[+]MP-532.60[+]29.89[+]M
C-631.93[+]28.99[+]MP-630.82[+]29.36[+]M
C-731.91[+]28.57[+]MP-732.47[+]29.00[+]M
C-835.95[–]32.27[+]UMP-831.66[+]28.34[+]M
C-931.25[+]29.97[+]MP-930.84[+]29.53[+]M
C-1029.84[+]27.52[+]MP-1032.65[+]29.36[+]M
C-1132.69[+]30.40[+]MP-1135.32[–]33.99[+]UM
C-1233.58[+]33.50[+]MP-1236.56[–]34.23[+]UM
C-1333.67[+]29.72[+]MP-1332.74[+]30.43[+]M
C-1434.55[+]30.58[+]MP-1434.57[+]32.49[+]M
C-1533.94[+]30.88[+]MP-1533.73[+]30.99[+]M
C-1633.88[+]29.60[+]MP-1635.42[–]33.56[+]UM
C-1734.66[+]32.72[+]MP-1735.56[–]31.58[+]UM
C-1832.31[+]29.43[+]MP-1834.46[+]31.25[+]M
C-1933.84[+]30.86[+]MP-1936.38[–]33.45[+]UM
C-2033.76[+]30.72[+]MP-2035.12[–]32.46[+]UM
C-2133.30[+]29.73[+]MP-2135.98[–]33.72[+]UM
C-2234.56[+]29.86[+]MP-2233.67[+]31.98[+]M
C-2333.40[+]30.30[+]MP-2334.28[+]31.94[+]M
C-2433.97[+]31.45[+]MP-2434.77[+]31.80[+]M
C-2533.30[+]30.37[+]MP-2533.33[+]31.58[+]M
C-2632.88[+]30.47[+]MP-2632.55[+]30.69[+]M
C-2732.35[+]31.44[+]MP-2733.65[+]31.66[+]M
C-2834.17[+]31.74[+]MP-2832.99[+]29.57[+]M
C-2933.24[+]30.55[+]MP-2933.22[+]28.42[+]M
C-3032.74[+]28.52[+]MP-3035.51[–]28.80[+]UM
C-3133.21[+]27.67[+]MP-3133.48[+]28.53[+]M
C-3235.24[+]30.34[+]UMP-3234.27[+]29.92[+]M
C-3332.86[–]27.26[+]MP-3332.63[+]27.98[+]M
C-3432.42[+]28.35[+]MP-3432.88[+]27.72[+]M
C-3532.29[+]28.39[+]MP-3533.68[+]29.86[+]M
C-3633.80[+]28.59[+]MP-3633.67[+]28.82[+]M
C-3734.38[+]27.65[+]MP-3734.92[+]30.58[+]M
C-3833.61[+]27.66[+]MP-3833.78[+]29.73[+]M
C-3933.81[+]28.85[+]MP-3935.75[–]28.32[+]UM
C-4032.49[+]28.40[+]MP-4034.72[+]29.49[+]M
C-4133.84[+]29.66[+]MP-4132.83[+]28.61[+]M
C-4234.29[+]28.94[+]MP-4235.31[–]30.58[+]UM
C-4333.97[+]29.58[+]MP-4332.45[+]27.63[+]M
C-4435.82[–]30.24[+]UMP-4433.76[+]29.67[+]M
C-4535.75[–]30.19[+]UMP-4532.99[+]28.25[+]M
C-4635.90[–]30.22[+]UMP-4633.71[+]28.53[+]M
C-4733.00[+]28.23[+]MP-4732.89[+]28.45[+]M
C-4833.59[+]29.34[+]M

Relation of the EGFR gene promoter methylation profile of patient group with age, gender and clinicopathological parameters.

ParametersnEGFR Methylation Profilep Value
MethylatedUnmethylated
Age:<50>50443334190.908a
Gender:malesfemales416334820.494a
Tumor stage:I-IIIII-IV20271423640.184a

The EGFR gene promoter methylation profile.

SampleEGFR Promoter Methylation Profile (%)p Value
MethylatedUnmethylated
Control43 (90.0);5 (10.0)0.121a
Patient37 (79.0)10 (21.0)

Clinicopathological parameters of the control and patient groups.

Control Group (n=48) (%)Patient Group (n=47) (%)
Gendermales: 36 (75.00); females: 12 (25.00)males: 41 (87.00); females: 6 (13.00)
Median age5859
Tumor typeLarynx: 31 (65.96)Hypopharynx: 5 (10.64)Lip: 3 (6.39)Tongue: 2 (4.26)Buccal: 2 (4.26)Auricular: 1 (2.13)Retromolar/oral: 1 (2.13)Paranasal sinus: 1 (2.13)Parotid gland: 1 (2.13)
Tumor stageT1: 10 (21.27)T2: 10 (21.27)T3: 20 (42.55)T4: 7 (14.89)
eISSN:
1311-0160
Lingua:
Inglese
Frequenza di pubblicazione:
2 volte all'anno
Argomenti della rivista:
Medicine, Basic Medical Science, other